● Live Tracking 375+ pre-IPO companies with institutional-grade data — updated daily. 140 in active pipeline.

Eikon Therapeutics IPO Status 2026

Drug discovery company using real-time single-molecule microscopy to unlock previously undruggable targets.

IndustryBiotechnology
StageSeries A
IPO StatusPrivate
Valuation$500M
Total Funding$73M
HeadquartersHayward, CA
CEORoger Pomerantz
How to Invest in Eikon Therapeutics
Pre-IPO
🔔 Get Notified When Eikon Therapeutics IPOs

No secondary market access for Eikon Therapeutics yet. Get instant alerts when an S-1 is filed or IPO date is announced.

Get IPO Alerts →
📡 IPO Intelligence
$49/mo — Unlimited Reports + Real-Time Updates
⚡Unlimited company analysis reports — all 375+ companies
✓Real-time IPO alerts — know the moment S-1s are filed
✓Verified data updated daily — not chatbot hallucinations
💡 Tracking multiple companies? Full access pays for itself after 3 reports.
$49
per month
Subscribe Now →
Cancel anytime · Secure via Stripe
Institutional Research
$19 — Get the Complete Eikon Therapeutics Analysis Brief
✓Executive summary & IPO readiness breakdown
✓Competitive positioning & funding trajectory
✓Bull / bear thesis with pricing projections
✓S-1 timeline estimate & risk assessment
$19
One-time
Secure checkout · Stripe · 24h delivery

Frequently Asked Questions

What is Eikon Therapeutics's current valuation? +

Eikon Therapeutics is valued at $500M as of March 2021.

How much total funding has Eikon Therapeutics raised? +

Eikon Therapeutics has raised $73M in total venture capital funding.

What sector is Eikon Therapeutics in? +

Eikon Therapeutics is a Biotechnology company. Drug discovery company using real-time single-molecule microscopy to unlock previously undruggable t.

What is Eikon Therapeutics's IPO readiness score? +

Eikon Therapeutics scores 54/100 on TechStackIPO's IPO readiness index, which evaluates funding stage, valuation trajectory, S-1 filing status, and market timing signals.